Last reviewed · How we verify

Placebo Matched to Low-Dose Cannabidiol — Competitive Intelligence Brief

Placebo Matched to Low-Dose Cannabidiol (Placebo Matched to Low-Dose Cannabidiol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabinoid. Area: Neurology.

phase 3 Cannabinoid CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo Matched to Low-Dose Cannabidiol (Placebo Matched to Low-Dose Cannabidiol) — Wayne State University. Cannabidiol (CBD) modulates endocannabinoid signaling and multiple receptor systems to produce therapeutic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo Matched to Low-Dose Cannabidiol TARGET Placebo Matched to Low-Dose Cannabidiol Wayne State University phase 3 Cannabinoid CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
MediCabilis CBD Oil MediCabilis CBD Oil Gold Coast Hospital and Health Service marketed Cannabinoid CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
Moderate-Dose Cannabidiol Moderate-Dose Cannabidiol Wayne State University phase 3 Cannabinoid CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
Cannabidiol (CBD) Extract Cannabidiol (CBD) Extract Milton S. Hershey Medical Center phase 3 Cannabinoid receptor modulator CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
MPL-001 (CBD: THC 25:1) MPL-001 (CBD: THC 25:1) McMaster University phase 3 Cannabinoid combination CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
Cannabidiol (CBD) Oil Capsules Cannabidiol (CBD) Oil Capsules McMaster University phase 3 Phytocannabinoid CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multi-target)
Marinol DRONABINOL Wellhouse Pharma marketed Cannabinoid [EPC] Cannabinoid receptors 1985-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabinoid class)

  1. Wayne State University · 3 drugs in this class
  2. Hôpital le Vinatier · 1 drug in this class
  3. Montefiore Medical Center · 1 drug in this class
  4. OMNI Medical Services, LLC · 1 drug in this class
  5. Gold Coast Hospital and Health Service · 1 drug in this class
  6. Stero Biotechs Ltd. · 1 drug in this class
  7. University of California, San Diego · 1 drug in this class
  8. University of Connecticut · 1 drug in this class
  9. Staci Gruber, Ph.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo Matched to Low-Dose Cannabidiol — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matched-to-low-dose-cannabidiol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: